跳至主要内容
临床试验/NCT02911545
NCT02911545已完成不适用

Non-vitamin K Oral Anticoagulants in Cardioversion of Atrial Fibrillation. FinCV3

Helsinki University Central Hospital0 个研究点目标入组 1,000 人开始时间: 2011年10月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,000
主要终点
Incidence and predictors of thromboembolic complications

研究概览

简要总结

Non-vitamin K oral anticoagulants (NOAC) have been shown to be safe and effective alternatives to warfarin for stroke prevention in patients with nonvalvular AF (NVAF). There are yet limited real life data on outcomes following elective cardioversion in AF patients treated with NOACs. The aim of this study is to investigate the complications and the use of NOACs in AF patients undergoing cardioversion.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • AF patients undergoing cardioversion

排除标准

  • 未提供

结局指标

主要结局

Incidence and predictors of thromboembolic complications

时间窗: 31 days after cardioversion of persistent AF

Incidence and predictors of bleeding

时间窗: 31 days after cardioversion of persistent AF

次要结局

  • Hemodynamic complications of cardioversion(31 days after cardioversion of persistent AF)
  • Number of recurrence of AF(31 days after cardioversion of persistent AF)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mika Lehto

MD, PhD, cardiologist

Helsinki University Central Hospital

相似试验